Korea Investment Partners co-invested in Elisigen's Series C round in January 2026.
Elisigen develops gene therapy products for neurological diseases, utilizing adeno-associated virus gene therapy to improve the quality of life for patients suffering from neurodegenerative disorders and other rare diseases
Elisigen develops gene therapy products for neurological diseases, utilizing adeno-associated virus gene therapy to improve the quality of life for patients suffering from neurodegenerative disorders and other rare diseases.